Lenire Tinnitus Treatment Device Now Available in The Netherlands
- Lenire tinnitus treatment device is now available in HearConsult Utrecht and Mijdrecht.
- 91% of compliant patients reported long lasting relief from tinnitus that sustained for at least 1-year in a large-scale clinical trial.1
- 91.5% of tinnitus patients reported significant relief from tinnitus in a peer-reviewed analysis of patients treated with Lenire at an independent clinic.2
- Tinnitus affects over 2 million adults in The Netherlands3 with reports suggesting incidences of tinnitus have increased by 33% between 2012 and 2021.4
- Expanding Lenire’s availability to The Netherlands is part of Neuromod’s ongoing strategy to expand Lenire’s footprint across Europe.
Tinnitus is on the rise in The Netherlands – but a new proven treatment method now available in The Netherlands offers hope.
Neuromod has partnered with HearConsult to make the Lenire tinnitus treatment device available in The Netherlands.
Lenire® is a groundbreaking bimodal neuromodulation device that has been proven to provide clinically significant relief from tinnitus across multiple clinical trials and with real world patients.1,2,5
Tinnitus, commonly known as ringing in the ears, affects over 2 million adults in the Netherlands. A recently published paper reported that tinnitus incidence in the Netherlands increased by 33% from 2012 to 2021. The authors attributed this rise to increased exposure to loud music, noise pollution, and evolving listening habits. They also found that the largest increase occurred among younger adults aged 20–44 years.
Expanding Lenire’s availability to The Netherlands is part of Neuromod’s ongoing strategy to expand Lenire’s footprint across Europe.
Jan van Dam, a Utrecht-based researcher tells his story of using Lenire to relieve his tinnitus.
Lenire Now Available in The Netherlands, Across Europe and the USA
The Netherlands is the latest country to make Lenire® available. The company launched the device in Denmark, Norway, Spain, Italy, Poland, Sweden, and Switzerland, and later expanded into the United Kingdom.
“There has been a significant increase of people whose primary concern is tinnitus in our clinic and this is common across all Dutch audiology practices,” said Koen Vernooij Au.D., owner of HearConsult. “We have seen the remarkable evidence from clinics across Europe and the United States and we are excited to make this proven treatment option available at our clinic.”
Utrecht-based researcher, Jan van Dam, spoke about his experience living with tinnitus for decades. Jan traveled to Belgium to receive treatment with Lenire before the device became available in the Netherlands.
“As a researcher, I spend quite a lot of time focusing in quiet spaces, and the noise from my tinnitus was very distracting, and it also made socialising difficult,” said Jan van Dam. “I found Lenire’s clinical research compelling and now, after treating my tinnitus with the device, the tinnitus is much quieter, and it no longer annoys me.”
Lenire Proven to Provide Long-term Relief from Tinnitus
Lenire is the first non-invasive bimodal neuromodulation tinnitus treatment device. Clinical trials and real-world patient analyses have proven the device effective. Lenire combines tongue and auditory stimulation through bimodal neuromodulation. This approach drives long-term changes in the brain and relieves tinnitus severity.
In 2023, Lenire made regulatory history by becoming the first and only bimodal neuromodulation device to be granted De Novo approval by the United States of America Food and Drug Administration (US FDA).
De Novo Approval from the FDA was granted based on the success of Lenire’s TENT-A3 controlled clinical trial. TENT-A3 demonstrated that Lenire was clinically superior for the treatment of tinnitus than sound-therapy, which was the trial’s control.5
Nature – Scientific Reports published results from Lenire’s second large-scale clinical trial, TENT-A2. TENT-A2 showed 95% of compliant patients reported tinnitus improvement. 91% reported long-term relief that sustained for at least a year after treatment ended.1
Nature Communications Medicine recently published the results of 220 tinnitus patients treated with Lenire in a real-world clinical setting. 91.5% of patients reported clinically meaningful reductions in tinnitus after treatment with Lenire.2
Tinnitus UK has rated Lenire as the top tinnitus treatment option for safety and effectiveness, acknowledging the evidence base.
Lenire is available in The Netherlands through HearConsult following a suitability assessment.
Tinnitus and Lenire Information Sessions in Mijdrecht
HearConsult is running 4 information sessions for patients with tinnitus on the 26th and 27th of March in Mijdrecht. There will be 2 sessions per day at 14:00 and 20:00. The sessions will cover the causes of tinnitus and the available treatment options. As well this, the session will feature tips for managing your tinnitus.
Attendance is free but places are limited and must be reserved in advance at https://www.hearconsult.nl/ Complimentary parking and refreshments provided.
About Neuromod Devices
Neuromod Devices is a global medical technology company with offices in Ireland and the USA. The company specialises in the design and development of neuromodulation technologies to address the clinical needs of tinnitus patients.
Neuromod has completed extensive clinical trials to confirm the safety and effectiveness of Lenire.
For more information about Neuromod visit www.neuromod.com.
Now Available in The Netherlands – About Lenire
Lenire® is the first non-invasive bimodal neuromodulation tinnitus treatment device shown to soothe and relieve tinnitus in large-scale clinical trials.
Bimodal neuromodulation stimulates nerves with two paired stimuli for therapeutic purposes. Lenire, the tinnitus treatment device used in the study, was developed by Neuromod Devices. The device uses wireless (Bluetooth®) headphones to deliver sequences of audio tones to both ears and delivers electrical stimulation pulses to the surface of the tongue through 32 electrodes on a proprietary device trademarked as Tonguetip. Clinicians can configure the device’s settings to provide treatment with different combinations of audio and electrical stimuli.
The easy-to-use handheld controller controls the timing, intensity, and delivery of the stimuli. Clinicians train each participant to use the controller before the participant continues treatment from home. An appropriately qualified healthcare professional, such as an audiologist or ENT surgeon, prescribes Lenire to patients with tinnitus after assessing their suitability. Patients then complete treatment from home between follow-up appointments with their clinician.
About HearConsult
HearConsult is a specialty tinnitus care clinic with locations in Mijdrecht and Utrecht. Founded by Koen Vernooij, AuD, a practitioner with over 30 years of experience in the hearing care sector, HearConsult focuses on personalised care, honesty, and education for tinnitus patients.
References
- Conlon et al., Different bimodal neuromodulation settings reduce tinnitus symptoms in a large randomized trial, Sci Rep, nature.com/articles/s41598-022-13875-x (2022)
- Mc Mahan, E., and Lim, H. Retrospective chart review demonstrating effectiveness of bimodal neuromodulation for tinnitus treatment, Commun Med (2025)
- R. Biswas et al., Tinnitus prevalence in Europe: a multi-country cross-sectional population study, The Lancet Regional Health (2021)
- Bes, J. et al, The impact of tinnitus on Dutch GPs: A retrospective study using routine healthcare data, https://doi.org/10.1371/journal.pone.0313630 (2024)
- Boedts, M., Beuchner, A., Khoo, S.G. et al Combining sound with tongue stimulation for the treatment of tinnitus. A multi-site single-arm controlled pivotal trial. Nature Comms. (2024)
